Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Rating of “Buy” by Brokerages

Royalty Pharma plc (NASDAQ:RPRXGet Rating) has been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $50.80.

Several equities analysts recently issued reports on RPRX shares. Zacks Investment Research lowered shares of Royalty Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, January 26th. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a report on Wednesday, April 27th. They set a “buy” rating and a $56.00 price objective on the stock. StockNews.com started coverage on shares of Royalty Pharma in a report on Thursday, March 31st. They set a “hold” rating on the stock. JPMorgan Chase & Co. raised shares of Royalty Pharma from a “neutral” rating to an “overweight” rating and set a $50.00 price objective on the stock in a report on Thursday, April 14th. They noted that the move was a valuation call. Finally, Morgan Stanley upgraded shares of Royalty Pharma from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $46.00 to $48.00 in a research note on Wednesday, April 6th.

Shares of NASDAQ:RPRX opened at $39.72 on Monday. The firm has a market cap of $24.12 billion, a PE ratio of 39.72, a price-to-earnings-growth ratio of 1.22 and a beta of 0.36. The firm’s 50 day simple moving average is $40.47 and its 200-day simple moving average is $39.94. Royalty Pharma has a one year low of $34.86 and a one year high of $47.10. The company has a debt-to-equity ratio of 0.69, a quick ratio of 16.81 and a current ratio of 16.81.

Royalty Pharma (NASDAQ:RPRXGet Rating) last issued its earnings results on Tuesday, February 15th. The biopharmaceutical company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $543.00 million for the quarter, compared to analyst estimates of $543.50 million. Royalty Pharma had a net margin of 26.46% and a return on equity of 16.67%. During the same period last year, the company posted $0.28 earnings per share. Equities research analysts predict that Royalty Pharma will post 3 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 15th. Shareholders of record on Friday, May 20th will be paid a $0.19 dividend. The ex-dividend date is Thursday, May 19th. This represents a $0.76 annualized dividend and a yield of 1.91%. Royalty Pharma’s dividend payout ratio (DPR) is 76.00%.

In other Royalty Pharma news, Director Henry A. Fernandez bought 32,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 24th. The stock was bought at an average cost of $37.49 per share, for a total transaction of $1,218,425.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rory B. Riggs sold 39,867 shares of the business’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $39.05, for a total transaction of $1,556,806.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 229,089 shares of company stock valued at $8,982,936. 25.86% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC increased its holdings in Royalty Pharma by 53.9% in the first quarter. Signaturefd LLC now owns 688 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 241 shares in the last quarter. Arizona State Retirement System increased its holdings in Royalty Pharma by 0.5% in the third quarter. Arizona State Retirement System now owns 49,613 shares of the biopharmaceutical company’s stock valued at $1,793,000 after buying an additional 246 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in Royalty Pharma by 0.8% in the third quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 32,621 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 265 shares in the last quarter. Humankind Investments LLC increased its holdings in Royalty Pharma by 4.6% in the fourth quarter. Humankind Investments LLC now owns 6,122 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 269 shares in the last quarter. Finally, Gulf International Bank UK Ltd increased its holdings in Royalty Pharma by 0.5% in the first quarter. Gulf International Bank UK Ltd now owns 57,580 shares of the biopharmaceutical company’s stock valued at $2,243,000 after buying an additional 300 shares in the last quarter. Institutional investors own 51.68% of the company’s stock.

Royalty Pharma Company Profile (Get Rating)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

See Also

Analyst Recommendations for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.